Blog

News and thought leadership from Icagen

A One-Year Journey to Nimble

A One-Year Journey to Nimble

July 15, 2017 marked the one-year anniversary of the divestiture of the Tucson Innovation Center from the fold of a Fortune 100 pharmaceutical company. A twenty-year journey of significant contribution in integrated drug discovery inside a large research organization was about to change. Our skills and expertise were acquired by a smaller..

Read More
Icagen on the Road to BIO: Early-Stage Planning for End-Stage Success

Icagen on the Road to BIO: Early-Stage Planning for End-Stage Success

Kenneth F. Wertman, Ph.D, speaks from Icagen's Tucson site about the importance of a fully integrated approach in identifying high quality drug candidates.

Read More
Early-Stage Planning for End-Stage Success

Early-Stage Planning for End-Stage Success

Icagen's integrated approach to early drug discovery combines chemistry, biology and computational science to help partners optimize efficiency moving from target to lead

Partnering in Early Discovery 

Many companies that have recently started to offer research services in North America are piecing together groups discipline by discipline, and..

Read More
Disease-In-A-Dish: Leveraging in vitro Human Models to Advance Drug Discovery

Disease-In-A-Dish: Leveraging in vitro Human Models to Advance Drug Discovery

Treatment of diseases, especially rare diseases, is very complex due to specific changes in the genetic makeup of the individual patient. As such, a more personalized approach to the generation of therapeutics is gaining greater traction not only with medical personnel, but also with the patient.

The term “personalized medicine” relates to the..

Read More
Integrated Innovation: Fostering the New Growth in Pharma

Integrated Innovation: Fostering the New Growth in Pharma

The pharma landscape is constantly changing, especially as many players in the industry move toward slimmed-down in-house R&D. This includes embracing the “growth pharma” model in which drug discovery programs are obtained via acquisitions. Many big pharma executives have left their posts to spearhead lean, high-risk, high-reward biotech firms,..

Read More
Disease in a Dish, Creating Human Tissues In Vitro

Disease in a Dish, Creating Human Tissues In Vitro

Pharma's Almanac interview at AAPS 2016 with Paul August, Ph.D, Vice President Biology, Icagen.

Read More
Transforming the Pharmaceutical Industry Pipeline with In Silico Approaches

Transforming the Pharmaceutical Industry Pipeline with In Silico Approaches

Fifteen years ago, the pharmaceutical industry was abuzz: Computational modeling was about to transform the drug-discovery paradigm. Compound modeling and screening in silico would save lives, years of research, millions of dollars in costs and largely put an end to animal testing.1 Yet, when in silico success stories didn’t start pouring in, a..

Read More
Teaming Up to Drive Drug Discovery for Rare Disease Patients: Rationale for Nonprofit Patient Foundations and Pharma/Biotech to Collaborate

Teaming Up to Drive Drug Discovery for Rare Disease Patients: Rationale for Nonprofit Patient Foundations and Pharma/Biotech to Collaborate

For many years now, I have been a staunch advocate for non-profit patient foundations and pharmaceutical companies to work together to advance drug discovery efforts that support the objectives of both organizations. Along these lines, I have worked to forge relationships between these types of disparate non-profit patient organizations and the..

Read More
Strategic Outsourcing Supports Pharma’s Focus on Internal Pipelines

Strategic Outsourcing Supports Pharma’s Focus on Internal Pipelines

Recent developments and headlines such as “Lilly's CEO keeps faith in the pipeline as biotech gets 'too expensive'” and “Leery of new deals, Roche spotlights its late-stage pipeline standoutssuggest that more drug companies are relying more on internal pipelines than M&A to remain competitive.   Given how many pharma companies have downsized..

Read More
Can Small Molecule-Reprogramming of Fibroblasts Create Better Drugs or Be Used to Treat Human Neuronal Disorders?

Can Small Molecule-Reprogramming of Fibroblasts Create Better Drugs or Be Used to Treat Human Neuronal Disorders?

A recent move in compound screening dictates the use more biologically relevant cells for drug discovery experiments, but as researchers know, it can be a challenge to obtain enough primary cells. Stem cells have been used to generate biologically relevant cells, but the process is time consuming and expensive.

Read More